Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 3/20 | 0.45 |
| ▸ | CDK8 | P49336 | 6/20 | 0.44 |
| ▸ | CCNC | P24863 | 5/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826717 | 0.97 | IP6K1 (0.48) | IP6K1CDK8CCNCIRAK4MAP4K4 | |
| SCHEMBL25826716 | 0.88 | CCNC (0.51) | CDK8CCNCMEN1KMT2AALDH1A1 | |
| SCHEMBL24006371 | 0.86 | ALDH1A1 (0.52) | IP6K1CDK8CCNCMAP4K4IP6K3 | |
| SCHEMBL25491134 | 0.83 | ALDH1A1 (0.56) | IP6K1CDK8CCNCMAP4K4IP6K3 | |
| SCHEMBL25821244 | 0.83 | LRRK2 (0.43) | IRAK4LRRK2 | |
| SCHEMBL26311806 | 0.82 | IP6K1 (0.51) | IP6K1CDK8CCNCMAP4K4IP6K3 | |
| SCHEMBL25831270 | 0.82 | ALDH1A1 (0.55) | IP6K1CDK8CCNCMAP4K4IP6K3 | |
| SCHEMBL25826720 | 0.80 | IRAK4 (0.38) | IRAK4TBK1 | |
| SCHEMBL25826722 | 0.80 | IRAK4 (0.43) | CDK8CCNCIRAK4TBK1 | |
| SCHEMBL25826713 | 0.80 | NCF1 (0.41) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | IP6K1 186/4885CDK8 567/4885CCNC 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.